Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Increased Body Mass Index Shows a Link to Breast Cancer

November 22, 2023
By Neil M. Iyengar, MD
Commentary
Video

Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      In an interview with CancerNetwork®, Neil M. Iyengar, associate professor of medicine at Memorial Sloan Kettering Cancer Center, spoke about the importance of exercise in mitigating adverse effects (AEs) related to cancer treatment. Iyengar highlighted his study, “Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2” to discuss the effects of body mass index as an established risk factor for breast cancer. Iyengar also discussed the relationship between exercise and genetic dispositions of cancer.

      The study found that there was mechanistic evidence between body mass index and patients who developed breast cancer with a BRCA mutation.

      Transcript:

      Exercise is an important component of taking care of one's own well-being. We’re also learning that exercise may be helpful for mitigating AEs related to cancer therapy and symptoms related to cancer.1 There is a growing body of evidence that [shows that] exercise may also have some direct anti-cancer activity. There are several professional bodies, like the American Society of Clinical Oncology [ASCO], the American Cancer Society, and the American College of Sports Medicine, that recommend exercise as part of a cancer treatment plan. We have conducted several research studies, as well as many other groups, which have demonstrated that exercise is feasible during cancer treatment, including during chemotherapy. It can be helpful for general well-being but may also help to improve response to cancer therapies, and that's an ongoing area or area of research right now.

      Whenever we publish our findings regarding lifestyle interventions in cancer, a very common question is: what about [patients] with a genetic predisposition, like a breast cancer gene [BRCA] mutation? Does it matter if they’re exercising, eating well, or doing other lifestyle or environmental-related [activities] when they have a genetic predisposition to developing certain types of cancer? This was the question that came from a lot of patients. That stimulated us to conduct this study, in collaboration with Kristy A. Brown’s lab [from Weill Cornell Medicine], to try and understand: do we see the same types of obesity-related inflammation and changes within the breast microenvironment that we do in [patients] who don’t have a genetic predisposition?2 We found that levels of DNA damage in the breast epithelium are increased in association with obesity, in association with insulin resistance independent of obesity in women who carry germline BRCA1/2 mutations. This suggests that these lifestyle components can further increase the risk or penetrance of BRCA-related cancers.

      References

      1. Iyengar NM. Inclusion of exercise in cancer treatment planning. JACC CardioOncol. 2022;4(4):504-506. doi:10.1016/j.jaccao.2022.10.002
      2. Bhardwaj P, Iyengar NM, Zahid H, et al. Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2. Sci Transl Med. 2023;15(684):eade1857. doi:10.1126/scitranslmed.ade1857
      Recent Videos
      Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
      Highlighting Breast Cancer Advances at IBC East
      Dissecting T-DXd/Dato-DXd Approvals in Breast Cancer
      Dissecting T-DXd/Dato-DXd Approvals in Breast Cancer
      Analyzing Emerging Therapies Across Breast Cancer Subtypes
      Analyzing Emerging Therapies Across Breast Cancer Subtypes
      Assessing ADC Combinations for Treatment in Breast Cancer
      Assessing ADC Combinations for Treatment in Breast Cancer
      Finding the Best Sequencing Options for ADCs Across Breast Cancer Subtypes
      Finding the Best Sequencing Options for ADCs Across Breast Cancer Subtypes
      Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
      Navigating Treatment Decision-Making for CDK4/6 Inhibitors in Breast Cancer
      An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
      CDK4/6 Inhibitors Moving Into Early-Stage Breast Cancer is a “Huge Advance”
      Expanding Immunotherapy Use in Early-Stage Breast Cancer
      Expanding Immunotherapy Use in Early-Stage Breast Cancer
      The Evolving Landscape of CDK4/6 Inhibitors in Adjuvant HR+/HER2– Breast Cancer
      The Evolving Landscape of CDK4/6 Inhibitors in Adjuvant HR+/HER2– Breast Cancer
      Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
      Clinical Data May Support PARP Inhibition in Somatic BRCA-Mutant TNBC
      Related Content
      Advertisement

      Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

      Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

      Russ Conroy
      July 24th 2025
      Article

      Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


      Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

      Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

      Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
      July 21st 2025
      Podcast

      Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


      The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

      T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

      Roman Fabbricatore
      July 18th 2025
      Article

      The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


      2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

      2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

      Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
      July 16th 2025
      Article

      3 Intraoperative Radiotherapy: Alive and Well in the Bronx

      3 Intraoperative Radiotherapy: Alive and Well in the Bronx

      Caroline Oska;Eleni Kohilakis;Jana Fox
      July 15th 2025
      Article
      Related Content
      Breast Cancer
      Advertisement

      Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

      Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

      Russ Conroy
      July 24th 2025
      Article

      Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


      Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

      Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

      Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
      July 21st 2025
      Podcast

      Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


      The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

      T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

      Roman Fabbricatore
      July 18th 2025
      Article

      The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


      2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

      2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

      Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
      July 16th 2025
      Article

      3 Intraoperative Radiotherapy: Alive and Well in the Bronx

      3 Intraoperative Radiotherapy: Alive and Well in the Bronx

      Caroline Oska;Eleni Kohilakis;Jana Fox
      July 15th 2025
      Article
      Advertisement
      Advertisement
      Advertisement
      Advertisement
      x
      About
      Advertise
      CureToday.com
      OncLive.com
      OncNursingNews.com
      TargetedOnc.com
      Editorial
      Contact
      Terms and Conditions
      Privacy
      Do Not Sell My Personal Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.